Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

INTRODUCTION: Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance therapy in patients in remission should be considered in order...

Descripción completa

Detalles Bibliográficos
Autores principales: Buhl, Sine Schnoor, Steenholdt, Casper, Brynskov, Jørn, Thomsen, Ole Østergaard, Bendtzen, Klaus, Ainsworth, Mark Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275671/
https://www.ncbi.nlm.nih.gov/pubmed/25524543
http://dx.doi.org/10.1136/bmjopen-2014-005887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275671/
https://www.ncbi.nlm.nih.gov/pubmed/25524543
http://dx.doi.org/10.1136/bmjopen-2014-005887

Ejemplares similares